The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines

The aberrant activation of the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathway is common in pancreatic ductal adenocarcinomas (PDAC). The application of inhibitors against PI3K and AKT has been considered as a therapeutic option. We investigated PDAC cell lines exposed to increasing...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yixuan, Sender, Sina, Sekora, Anett, Kong, Weibo, Bauer, Peter, Ameziane, Najim, Al-Ali, Ruslan, Krake, Susann, Radefeldt, Mandy, Weiss, Frank Ulrich, Lerch, Markus M., Parveen, Alisha, Zechner, Dietmar, Junghanss, Christian, Murua Escobar, Hugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029322/
https://www.ncbi.nlm.nih.gov/pubmed/35457111
http://dx.doi.org/10.3390/ijms23084295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029322/
https://www.ncbi.nlm.nih.gov/pubmed/35457111
http://dx.doi.org/10.3390/ijms23084295

Ejemplares similares